Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641076 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
A Phase 3 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 960
- Enrollment target
- 20
- Study locations
NCT06641076: Active Phase 3 study of Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics.
NCT06641076 is a Phase 3 study of Arthritis, Psoriatic that is active but no longer recruiting, run by MoonLake Immunotherapeutics. The registered enrollment target is 960 participants, above the 516-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06641076, a Phase 3 study of Arthritis, Psoriatic, is active but no longer recruiting, sponsored by MoonLake Immunotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 960 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
Primary Outcome
Proportion of participants achieving ACR50
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sonelokimab
Study Locations (20)
Arizona
- Clinical Site - Avondale
- Clinical Site - Chandler
- Clinical Site - Flagstaff
- Clinical Site - Mesa
- Clinical Site - Phoenix
- Clinical Site - Scottsdale
- Clinical Site - Tucson
Florida
- Clinical Site - Avon Park
- Clinical Site - Clearwater
- Clinical Site - Hialeah
- Clinical Site - Tampa
North Carolina
- Clinical Site - Leland
- Clinical Site - Salisbury
- Clinical Site - Statesville
California
- Clinical Site - San Diego
- Clinical Site - Upland
Illinois
- Clinical Site - Springfield
Louisiana
- Clinical Site - Lake Charles
Maryland
- Clinical Site - Baltimore
Michigan
- Clinical Site - Grand Blanc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2024-10-15 |
| Est. Completion | 2027-02-04 |
| Phase | Phase 3 |
What the registry record for NCT06641076 still lists
NCT06641076 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, above the 516-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target (86% higher).
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06641076 names 20 study sites across 8 states, led by Arizona, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06641076 about?
NCT06641076 is a clinical study titled "Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug". This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.
What is the current status of trial NCT06641076?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2024-10-15. Estimated completion is 2027-02-04.
What conditions does trial NCT06641076 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT06641076?
The interventions under investigation include: Placebo (DRUG), Sonelokimab (DRUG).
Who is sponsoring clinical trial NCT06641076?
This trial is sponsored by MoonLake Immunotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641076 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06641076's enrollment target sits among peer trials
960 3rd of 16 higher than 14 of 16 other Arthritis, Psoriatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Psoriatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI